Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial
Abstract Ixazomib‐lenalidomide‐dexamethasone (ixazomib‐Rd) showed clinical efficacy over placebo‐Rd in patients with relapsed/refractory multiple myeloma (MM) in the TOURMALINE‐MM1 trial. Over a median follow‐up of ∼85 months, as patients showed disease progression, they received subsequent novel th...
Gardado en:
| Principais autores: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Wiley
2022-11-01
|
| Series: | eJHaem |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1002/jha2.548 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|